3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxy-N-(2-pyrrolidin-1-ylpropan-2-yl)benzenesulfonamide;hydrate;hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxy-N-(2-pyrrolidin-1-ylpropan-2-yl)benzenesulfonamide;hydrate;hydrochloride
• 化学式: C25H39ClN6O5S
• 分子量: 571.1
• InChiKey: WFFPJLPUJSSPCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.77
• 重原子数：
  38
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  127
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• SALT AND POLYMORPH OF PYRAZOLOPYRIMIDINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF
  申请人：Li Jianfeng

  公开号：US20140309241A1

  公开（公告）日：2014-10-16

  The present invention relates to new salts of pyrazolopyrimidinone represented by formula (I), and pharmaceutically acceptable polymorph, solvate, hydrate, dehydrate, co-crystallization, anhydrous, or amorphous form thereof, the pharmaceutical compositions, and a pharmaceutical unit dosage form containing the same, wherein x represents organic or inorganic acids, preferable maleic acid, succinic acid, methanesulfonic acid, hydrochloric acid, etc. The invention further relates to co-crystals or complexes of compounds of pyrazolopyrimidinone and pharmaceutical compositions containing the same. The present invention also relates to a process for the preparation, use thereof and pharmaceutical preparation containing the salts or crystalline forms.

  本发明涉及由式(I)表示的吡唑吡咯嘧啶酮的新盐，以及药学上可接受的多形态、溶剂化合物、水合物、脱水物、共结晶物、无水物或非晶形式，药物组合物，以及含有相同物质的药物单剂量形式，其中x代表有机或无机酸，优选马来酸、琥珀酸、甲磺酸、盐酸等。该发明还涉及吡唑吡咯嘧啶酮化合物的共晶或复合物以及含有相同物质的药物组合物。本发明还涉及制备过程、使用方法以及含有盐或晶体形式的药物制剂。
• SALT AND POLYMORPH OF PYRAZOLOPYRIMIDINONE COMPOUND AND DRUG COMPOSITION, PREPARATION METHOD AND USE THEREOF
  申请人：Topharman Shanghai Co., Ltd.

  公开号：EP2746284A1

  公开（公告）日：2014-06-25

  The present invention relates to new salts of pyrazolopyrimidinone represented by formula (I), and pharmaceutically acceptable polymorph, solvate, hydrate, dehydrate, co-crystallization, anhydrous, or amorphous form thereof, the pharmaceutical compositions, and a pharmaceutical unit dosage form containing the same, wherein x represents organic or inorganic acids, preferable maleic acid, succinic acid, methanesulfonic acid, hydrochloric acid, etc. The invention further relates to co-crystals or complexes of compounds of pyrazolopyrimidinone and pharmaceutical compositions containing the same. The present invention also relates to a process for the preparation, use thereof and pharmaceutical preparation containing the salts or crystalline forms.

  本发明涉及式(I)代表的吡唑嘧啶酮的新盐及其药学上可接受的多晶型、溶解物、水合物、脱水物、共晶体、无水物或无定形形式、药物组合物和含有相同物质的药物单位剂型，其中x代表有机酸或无机酸，优选马来酸、琥珀酸、甲磺酸、盐酸等。本发明还涉及吡唑嘧啶酮化合物的共晶体或络合物以及含有这些化合物的药物组合物。本发明还涉及一种制备工艺、其用途和含有这些盐或结晶形式的药物制剂。
• US9527849B2
  申请人：——

  公开号：US9527849B2

  公开（公告）日：2016-12-27